Dr. Violeta Rus, M.D.
Rheumatology (Rheumatology Physician)
22 S Greene St
Baltimore, MD 21201
Who else practices at this address →
Baltimore city includes primary care (36% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 47
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 70
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Rheumatology Physician primary
MD license D51494
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Maryland Medical Center Baltimore, MD
- University of MD Medical Center Midtown Campus Baltimore, MD
- Umd Rehabilitation & Orthopaedic Institute Baltimore, MD
Medical groups
- University of Maryland Physicians PA (404 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 70
- Services billed
- 153
- Patients’ average age
- 63
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 96 | 48 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Hydroxychloroquine Sulfate Other prescribers in Baltimore, MD | 131 |
| Prednisone Other prescribers in Baltimore, MD | 58 |
| Benlysta (belimumab) | 41 |
| Mycophenolate Mofetil Other prescribers in Baltimore, MD | 35 |
| Tramadol Hcl Other prescribers in Baltimore, MD | 34 |
| Cyclobenzaprine Hcl Other prescribers in Baltimore, MD | 29 |
| Celecoxib Other prescribers in Baltimore, MD | 26 |
| Colchicine Other prescribers in Baltimore, MD | 22 |
| Methotrexate (methotrexate sodium) Other prescribers in Baltimore, MD | 21 |
| Diclofenac Sodium Other prescribers in Baltimore, MD | 20 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $115 in total to this clinician.
| Genzyme Corporation | $115 |
|---|
| Food and Beverage | $115 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $63,114 in research payments for these studies, mostly to the institutions running them.
- Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
AbbVie Inc. · Active, not recruiting · NCT05843643 - M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE)
AbbVie Inc. - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE)
AbbVie Inc. - A Randomized, Double-blind, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIR…
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.